Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
This security has been delisted
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

Roche Holding AG

WKN: A4124Y / Name: Roche Holding / Stock / ? /

€16.90
-0.590%

1 0
1
0
Roche Holding AG

WKN: A40CGQ / Name: Roche Holding / Stock / ? /

€8.00
-0.620%

0 0
0
0
Roche Holding AG ADR

WKN: 891106 / Symbol: RHHBY / Name: Roche / Stock / Pharmaceuticals / Large Cap /

€48.80
0.210%

4 3
4
3
Resurs Holding AB

WKN: A2AHSD / Name: Resurs Holding AB / Stock / Banking Services / Small Cap /

€3.14
-0.790%

0 0
0
0
Scholar Rock Holding

WKN: A2JMQW / Symbol: SRRK / Name: Scholar Rock / Stock / Small Cap /

€40.40
3.170%

21 0
21
0
VZ Holding AG

WKN: A2P272 / Name: Holding / Stock / ? /

€156.60
-1.880%

0 0
0
0
Rvrc Holding Ab

WKN: A3CR3B / Name: Rvrc Holding Ab / Stock / ? /

€6.14
-0.410%

0 0
0
0
Bachem Holding AG

WKN: A3DLKE / Name: Bachem Holding / Stock / ? /

€73.25
-0.210%

0 0
0
0
Rc365 Holding Plc

WKN: A3DH6R / Name: Rc365 Holding Plc / Stock / ? /

€0.017
0.000%

0 0
0
0
Bachem Holding AG

WKN: A3D9JM / Name: Bachem Holding / Stock / ? /

€6.00
-7.690%

0 0
0
0
ON Holding AG

WKN: A3C20K / Name: ON Holding / Stock / ? /

€36.80
0.270%

1 0
1
0
Roche Reports Upbeat Efficacy Data From Phase II Obesity Study
Roche Reports Upbeat Efficacy Data From Phase II Obesity Study

Roche Holding AG RHHBY announced positive top-line data from a mid-stage study of its investigational candidate, CT-388, being developed for the treatment of obesity. CT-388 is a once-weekly

Zacks 
0 28.01.26
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2025 mit Verkaufswachstum von 7%
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2025 mit Verkaufswachstum von 7%
  • Konzernverkäufe stiegen um 7%1 zu konstanten Wechselkursen (CER; 2% in CHF) dank hoher Nachfrage nach Medikamenten und diagnostischen Lösungen.
  • Im vierten Quartal nahm der Umsatz um 8% zu und
GlobeNewswire 
0 29.01.26
RHHBY's 2025 Results Hit by Currency Headwinds, Sales Up 7% at CER
RHHBY's 2025 Results Hit by Currency Headwinds, Sales Up 7% at CER

Swiss pharma giant Roche Holding AG's RHHBY 2025 results were affected by currency headwinds.

Sales totaled $74.4 billion, which missed the Zacks Consensus Estimate of $81.4 billion. Earnings per

Zacks 
0 29.01.26
Trading Rvrc Holding Ab

Trading Rvrc Holding Ab

investresearch
06.02.26